NZ552658A - IL-17 antagonistic antibodies - Google Patents

IL-17 antagonistic antibodies

Info

Publication number
NZ552658A
NZ552658A NZ552658A NZ55265805A NZ552658A NZ 552658 A NZ552658 A NZ 552658A NZ 552658 A NZ552658 A NZ 552658A NZ 55265805 A NZ55265805 A NZ 55265805A NZ 552658 A NZ552658 A NZ 552658A
Authority
NZ
New Zealand
Prior art keywords
amino acid
seq
acid sequence
human
cdr3
Prior art date
Application number
NZ552658A
Other languages
English (en)
Inventor
Padova Franco E Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ552658(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ552658A publication Critical patent/NZ552658A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ552658A 2004-08-05 2005-08-04 IL-17 antagonistic antibodies NZ552658A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
PCT/EP2005/008470 WO2006013107A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
NZ552658A true NZ552658A (en) 2009-11-27

Family

ID=32982602

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ552658A NZ552658A (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Country Status (40)

Country Link
US (9) US7807155B2 (OSRAM)
EP (5) EP3409288A1 (OSRAM)
JP (1) JP4682200B2 (OSRAM)
KR (2) KR20080029018A (OSRAM)
CN (1) CN101001645B (OSRAM)
AR (1) AR050200A1 (OSRAM)
AT (1) ATE517924T1 (OSRAM)
AU (2) AU2005268857C1 (OSRAM)
BE (1) BE2015C041I2 (OSRAM)
BR (3) BR122017009404B1 (OSRAM)
CA (1) CA2573586C (OSRAM)
CY (6) CY1111963T1 (OSRAM)
DK (4) DK1776142T6 (OSRAM)
EC (1) ECSP077198A (OSRAM)
ES (4) ES2367440T7 (OSRAM)
FR (1) FR15C0048I2 (OSRAM)
GB (1) GB0417487D0 (OSRAM)
HK (1) HK1256639A1 (OSRAM)
HR (3) HRP20110758T4 (OSRAM)
HU (4) HUE038187T2 (OSRAM)
IL (1) IL180717A (OSRAM)
LT (3) LT2902039T (OSRAM)
LU (2) LU92768I2 (OSRAM)
MA (1) MA28982B1 (OSRAM)
MX (1) MX2007001338A (OSRAM)
MY (1) MY144925A (OSRAM)
NL (1) NL300749I2 (OSRAM)
NO (9) NO336279B1 (OSRAM)
NZ (1) NZ552658A (OSRAM)
PE (1) PE20060418A1 (OSRAM)
PL (4) PL2364729T6 (OSRAM)
PT (4) PT2902039T (OSRAM)
RU (2) RU2426741C3 (OSRAM)
SG (1) SG155186A1 (OSRAM)
SI (4) SI2364729T1 (OSRAM)
TN (1) TNSN07034A1 (OSRAM)
TR (1) TR201808057T4 (OSRAM)
TW (1) TWI359153B (OSRAM)
WO (1) WO2006013107A1 (OSRAM)
ZA (1) ZA200700242B (OSRAM)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP2009507023A (ja) * 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
ES2672221T3 (es) * 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
PT2532681E (pt) 2005-12-20 2014-12-23 Sbi Biotech Co Ltd Anticorpos anti-ilt7
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
ES2373069T3 (es) 2006-08-11 2012-01-31 Schering Corporation Anticuerpos para il-17a.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
KR20160017119A (ko) 2007-05-29 2016-02-15 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA3069576A1 (en) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CA2717987C (en) * 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение
KR101579771B1 (ko) 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
ES2655877T3 (es) * 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20120093932A (ko) * 2009-10-10 2012-08-23 일레븐 바이오테라피틱스, 아이엔씨. Ｉｌ－１７ 패밀리 사이토카인 조성물들 및 용도들
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN102905727B (zh) 2009-10-30 2016-12-07 詹森生物科技公司 Il-17a拮抗剂
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103154026B (zh) * 2010-08-05 2016-07-06 安奈普泰斯生物有限公司 抗il-17的抗体
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
HUE044038T2 (hu) * 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
WO2012095507A1 (en) * 2011-01-13 2012-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
ES2632583T3 (es) 2011-01-14 2017-09-14 Ucb Biopharma Sprl Anticuerpo que se une a IL-17A e IL-17F
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
US9624261B2 (en) * 2011-03-29 2017-04-18 Glaxosmithkline Llc Buffer system for protein purification
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP2838560A2 (en) 2012-04-20 2015-02-25 Novartis AG Methods of treating ankylosing spondylitis using il-17 antagonists
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
HRP20192076T1 (hr) 2013-02-08 2020-02-07 Novartis Ag Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2015022656A1 (en) * 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
CN105705518A (zh) 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
RS61034B1 (sr) * 2013-11-18 2020-12-31 Shanghai hengrui pharmaceutical co ltd Il-17a vezujuće sredstvo i njegove upotrebe
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
KR20230170796A (ko) 2014-09-10 2023-12-19 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
PL3245224T3 (pl) 2015-01-12 2021-01-25 Affibody Ab Polipeptydy wiążące il-17a
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2018000694A (es) 2015-07-16 2018-05-07 Lilly Co Eli Tratamiento del prurito.
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
JP6858766B2 (ja) 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
KR102866147B1 (ko) 2016-03-10 2025-09-30 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
ES2992409T3 (es) 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
EA201990673A1 (ru) 2016-09-14 2019-08-30 Бэйцзин Ханми Фарм. Ко., Лтд. Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
UA126574C2 (uk) 2017-02-10 2022-11-02 Дженентек, Інк. Антитіло проти триптази, його композиція та застосування
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
WO2019087133A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
SG11202005005YA (en) 2017-11-30 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3773717A4 (en) * 2018-03-29 2022-05-11 REMD Biotherapeutics, Inc. TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A).
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
US12473357B2 (en) 2018-09-25 2025-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
IL320091A (en) 2019-01-31 2025-06-01 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
MX2022001068A (es) 2019-07-26 2022-02-14 Sinocelltech Ltd Anticuerpo anti-il17a humanizado y uso del mismo.
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
WO2021060425A1 (ja) * 2019-09-25 2021-04-01 国立大学法人東京大学 全身性強皮症治療用医薬組成物
CN114729943B (zh) 2019-09-30 2025-07-22 詹森药业有限公司 用大分子调节剂进行il-17靶接合测定的组合物和方法
AU2020386669A1 (en) 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
EP4069737A2 (en) 2019-12-06 2022-10-12 Novartis AG Methods of treating lichen planus using interleukin-17 (il-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
EP4168117A1 (en) 2020-06-23 2023-04-26 Novartis AG Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
JP2023554489A (ja) 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
CN119137115A (zh) 2022-04-25 2024-12-13 诺华股份有限公司 Il-17抑制剂的晶型
JP2025516772A (ja) 2022-05-16 2025-05-30 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いて巨細胞性動脈炎を治療する方法
KR20250011948A (ko) 2022-05-18 2025-01-22 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법
EP4406553A1 (en) * 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en) * 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
GB202407664D0 (en) 2024-05-30 2024-07-17 Fresenius Kabi Deutschland Gmbh Post-translational control of recombiant proteins
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
EP1591529A3 (en) * 1995-07-19 2005-11-09 Genetics Institute, LLC Human CLTA-8 and uses of CTLA-8-related proteins
DE69623316T2 (de) 1995-10-27 2003-04-17 Institut National De La Sante Et De La Recherche Medicale I.N.S.E.R.M., Paris Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE429241T1 (de) 1996-11-27 2009-05-15 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid- erzeugung
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
ATE320270T1 (de) 1997-11-10 2006-04-15 Cytimmune Sciences Inc Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
AU2004799A (en) 1997-12-19 1999-07-12 Millennium Biotherapeutics, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
AU2315099A (en) 1998-01-09 1999-07-26 Immunex Corporation Il-17rh dna and polypeptides
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
CA2328496C (en) 1998-05-15 2016-01-05 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
CA2706859A1 (en) 1998-09-17 2000-03-23 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
CN1357042A (zh) 1999-01-11 2002-07-03 先灵公司 白介素－17相关哺乳动物细胞因子、编码其的多核苷酸、应用
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
ATE412433T1 (de) 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
DE60125563T2 (de) 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
JP2004517918A (ja) * 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
EP1359938B1 (en) 2001-01-25 2011-03-16 ZymoGenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
PT1391464E (pt) * 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
WO2005023177A2 (en) * 2003-05-21 2005-03-17 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
JP4833850B2 (ja) 2003-11-21 2011-12-07 ユセベ ファルマ ソシエテ アノニム Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
AU2005241020B2 (en) * 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2009507023A (ja) * 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用

Also Published As

Publication number Publication date
HUS1500037I1 (hu) 2017-10-30
TNSN07034A1 (en) 2008-06-02
FR15C0048I2 (fr) 2015-11-20
LUC00088I2 (OSRAM) 2018-12-17
PL1776142T3 (pl) 2011-12-30
KR20070036166A (ko) 2007-04-02
BR122017009404B1 (pt) 2022-02-22
US20230235038A1 (en) 2023-07-27
AU2010201689A1 (en) 2010-05-20
NO337129B1 (no) 2016-01-25
US8617552B2 (en) 2013-12-31
NO20070985L (no) 2007-03-30
RU2011113153A (ru) 2012-10-20
NL300749I2 (nl) 2017-11-02
RU2426741C2 (ru) 2011-08-20
PL1776142T4 (pl) 2018-04-30
GB0417487D0 (en) 2004-09-08
US10344084B2 (en) 2019-07-09
TR201808057T4 (tr) 2018-06-21
DK1776142T3 (da) 2011-10-31
HRP20150480T1 (hr) 2015-07-17
JP2008507988A (ja) 2008-03-21
NO337286B1 (no) 2016-02-29
AU2005268857B8 (en) 2010-05-27
EP2366405A3 (en) 2012-01-18
US9765140B2 (en) 2017-09-19
CY2018027I1 (el) 2020-05-29
SI1776142T1 (sl) 2011-11-30
US20140079719A1 (en) 2014-03-20
PT2902039T (pt) 2018-07-17
US20090280131A1 (en) 2009-11-12
RU2426741C3 (ru) 2017-11-15
BRPI0513078B8 (pt) 2019-08-27
ES2367440T3 (es) 2011-11-03
DK2366405T3 (en) 2015-05-11
PT2366405E (pt) 2015-06-30
HUS1800040I1 (hu) 2018-11-28
CY2015030I1 (el) 2015-11-04
WO2006013107A1 (en) 2006-02-09
EP2902039B1 (en) 2018-04-11
HK1256639A1 (en) 2019-09-27
ATE517924T1 (de) 2011-08-15
NO2018007I1 (no) 2018-02-14
NO20171697A1 (no) 2007-03-30
BRPI0513078C1 (pt) 2021-05-25
LTPA2015029I1 (lt) 2022-07-11
KR20080029018A (ko) 2008-04-02
CN101001645A (zh) 2007-07-18
HRP20110758T1 (en) 2011-11-30
PL2902039T3 (pl) 2018-09-28
AU2010201689B2 (en) 2011-09-29
AU2005268857B2 (en) 2010-01-28
MA28982B1 (fr) 2007-11-01
EP2366405A2 (en) 2011-09-21
US20190270804A1 (en) 2019-09-05
TW200617025A (en) 2006-06-01
SI2366405T1 (sl) 2015-07-31
PL2364729T6 (pl) 2016-06-30
CA2573586A1 (en) 2006-02-09
HK1207559A1 (en) 2016-02-05
US20120107325A1 (en) 2012-05-03
CY1116256T1 (el) 2017-02-08
PT1776142E (pt) 2011-10-06
SI2364729T1 (sl) 2014-08-29
MY144925A (en) 2011-11-30
NO336279B1 (no) 2015-07-06
US20170355762A1 (en) 2017-12-14
EP2364729B1 (en) 2014-05-14
AR050200A1 (es) 2006-10-04
NO2015023I2 (no) 2015-10-26
US7807155B2 (en) 2010-10-05
PL1776142T6 (pl) 2016-06-30
SI2902039T1 (en) 2018-07-31
ES2487533T7 (es) 2015-07-14
NO2015023I1 (no) 2015-11-02
EP1776142B1 (en) 2011-07-27
PL2364729T3 (pl) 2014-10-31
NO20150064L (no) 2007-03-30
EP2366405B1 (en) 2015-02-25
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
EP2364729B3 (en) 2015-06-24
DK2364729T3 (da) 2014-07-21
BE2015C041I2 (OSRAM) 2024-10-08
EP1776142B3 (en) 2015-06-24
NO341384B1 (no) 2017-10-30
HRP20110758T4 (hr) 2015-07-31
ES2367440T7 (es) 2015-07-14
NO348010B1 (no) 2024-06-17
ES2487533T3 (es) 2014-08-21
EP3409288A1 (en) 2018-12-05
ECSP077198A (es) 2007-02-28
BR122018075556B1 (pt) 2022-10-18
CN101001645B (zh) 2012-09-05
MX2007001338A (es) 2008-03-11
ES2367440T9 (es) 2021-04-28
HUE038187T2 (hu) 2018-10-29
LT2902039T (lt) 2018-06-25
ZA200700242B (en) 2008-08-27
CY1120723T1 (el) 2019-12-11
NO2016017I1 (no) 2016-08-23
US8119131B2 (en) 2012-02-21
DK2364729T6 (en) 2015-07-06
US20250122277A1 (en) 2025-04-17
TWI359153B (en) 2012-03-01
NO20151787L (no) 2006-02-06
AU2005268857A1 (en) 2006-02-09
KR100852523B1 (ko) 2008-08-14
EP1776142B9 (en) 2016-09-07
BRPI0513078A (pt) 2008-04-22
CY2018027I2 (el) 2020-05-29
EP1776142A1 (en) 2007-04-25
IL180717A (en) 2012-07-31
FR15C0048I1 (fr) 2015-08-28
SG155186A1 (en) 2009-09-30
KR100852523B9 (ko) 2025-03-28
CY2015030I2 (el) 2017-11-14
EP2364729A2 (en) 2011-09-14
HUE025815T2 (en) 2016-04-28
ES2536228T3 (es) 2015-05-21
CY1115444T1 (el) 2017-01-04
CY1111963T1 (el) 2015-11-04
LU92768I2 (fr) 2015-11-03
EP2902039A1 (en) 2015-08-05
EP2364729A3 (en) 2012-01-18
US20150152178A1 (en) 2015-06-04
DK2902039T3 (en) 2018-07-16
IL180717A0 (en) 2007-06-03
PL2366405T3 (pl) 2015-08-31
LTPA2018515I1 (lt) 2018-10-25
CA2573586C (en) 2013-06-25
LTC1776142I2 (lt) 2022-07-11
JP4682200B2 (ja) 2011-05-11
PE20060418A1 (es) 2006-06-15
PT2364729E (pt) 2014-09-01
US20100215666A1 (en) 2010-08-26
DK1776142T6 (en) 2015-07-06
HK1101277A1 (en) 2007-10-12
AU2005268857C1 (en) 2012-01-19
HRP20181069T1 (hr) 2018-09-07
ES2677245T3 (es) 2018-07-31
NO20150065L (no) 2007-03-30
BRPI0513078B1 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
US20250122277A1 (en) Interleukin-17 (il-17) antagonistic antibodies
HK1207559B (en) Il-17 antagonistic antibodies
HK1101277B (en) Il-17 antagonistic antibodies

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2016 BY CPA GLOBAL

Effective date: 20150703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2017 BY CPA GLOBAL

Effective date: 20160701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2018 BY CPA GLOBAL

Effective date: 20170720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2019 BY CPA GLOBAL

Effective date: 20180719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2020 BY CPA GLOBAL

Effective date: 20190718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2021 BY CPA GLOBAL

Effective date: 20200716

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2022 BY CPA GLOBAL

Effective date: 20210722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2023 BY CPA GLOBAL

Effective date: 20220721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2024 BY CPA GLOBAL

Effective date: 20230720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240718

EXPY Patent expired